Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $30.0 million.

  • Indivior Pharmaceuticals' Other Non-Current Liabilities rose 10952.38% to $30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0 million, marking a year-over-year increase of 10952.38%. This contributed to the annual value of $18.0 million for FY2024, which is 4193.55% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Other Non-Current Liabilities stood at $30.0 million, which was up 10952.38% from $18.0 million recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Other Non-Current Liabilities peaked at $474.0 million during Q4 2021, and registered a low of -$369.0 million during Q3 2023.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $17.5 million (2024), whereas its average is -$55.2 million.
  • In the last 5 years, Indivior Pharmaceuticals' Other Non-Current Liabilities plummeted by 9275.7% in 2023 and then skyrocketed by 10952.38% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Other Non-Current Liabilities stood at $474.0 million in 2021, then decreased by 9.7% to $428.0 million in 2022, then tumbled by 92.76% to $31.0 million in 2023, then plummeted by 41.94% to $18.0 million in 2024, then soared by 66.67% to $30.0 million in 2025.
  • Its last three reported values are $30.0 million in Q3 2025, $18.0 million for Q2 2025, and $17.0 million during Q1 2025.